SOLANA BEACH, Calif., Sept. 06, 2016 -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at the Lotte New York Palace Hotel in New York City.
Mr. Gonyer will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 18th Annual Rodman & Renshaw Global Investment Conference
Date: Monday, September 12, 2016
Time: 2:10-2:35pm ET
Location: Holmes I; Lotte New York Palace Hotel in New York City
A copy of the corporate presentation will be posted to the Company's website prior to the conference.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.
Investor Contact: The Ruth Group David Burke O: 646-536-7009 C: 917-618-2651 [email protected]


MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 



